|
Official Course
Description: MCCCD Approval: 2-28-06 |
|||
|
DMI271
2006 Summer I – 2009 Summer
II |
LEC |
3.0 Credit(s) |
3.0 Period(s) |
|
Nuclear
Medicine Imaging II |
|||
|
Endocrine/exocrine,
gastrointestinal/accessory organ, and imaging. Review of related body system
anatomy, physiology and pathology. Endocrine/exocrine studies to include
thyroid uptake, thyroid scan, thyroid therapy, parathyroid imaging, adrenal
imaging, and lacrimal duct imaging.
Gastrointestinal/accessory organ studies to include salivary gland,
esophageal motility/transit and reflux, gastric emptying, helicobacter pylori
detection, liver/spleen imaging, hemangima
detection, hepatobiliary imaging, gastrointestinal
hemorrhage, Meckel's diverticulum,
Le Veen Shunt, and intrahepatic
pump study. Genitourinary system studies to include renal perfusion, renogram, glomerular filtration
rate (GFR), effective renal plasma flow (ERPF), renal scan for morphology,
voiding cystogram, testicular imaging. Prerequisites: DMI267 or permission of
Nuclear Medicine Technology program director. |
|||
Go to Competencies Go to Outline
|
MCCCD
Official Course Competencies: |
|
|
|
|
|
DMI271 2006
Summer I – 2009 Summer II |
Nuclear Medicine Imaging II |
|
1.
|
Discuss the gross anatomy and physiology of the
endocrine/exocrine, gastrointestinal/accessory organ and genitourinary
systems as they relate to nuclear medicine studies. (I, VIII, XXI) |
|
2.
|
Describe the characteristics and causes of common
pathologies of the endocrine/exocrine, gastrointestinal/accessory organ and
genitourinary systems related to nuclear medicine procedures including
susceptible populations and potential treatments. (II, IX, XXII) |
|
3.
|
List the indications for performing selected
endocrine/exocrine, gastrointestinal/accessory organ and genitourinary
systems. (III-VII, XXIII-XXX) |
|
4.
|
Discuss why a nuclear medicine study would be preferable
to or compliment other diagnostic modalities in various cases. (III-VII,
XXIII-XXX) |
|
5.
|
Describe the radiopharmaceuticals used for
endocrine/exocrine, gastrointestinal/accessory organ, and genitourinary
systems including biorouting dose preparation, and
route and method of administration. (III-VII, XXIII-XXX) |
|
6.
|
Specify the dose range for endocrine/exocrine,
gastrointestinal/accessory organ, and genitourinary systems and the resulting
radiation doses to various organs and tissues. (III-VII, XXIII-XXX) |
|
7.
|
Describe patient preparation for selected
endocrine/exocrine, gastrointestinal/accessory organ and genitourinary
studies. (III-VII, XXIII-XXX) |
|
8.
|
Describe the procedures for selected endocrine/exocrine, gastrointestinal/accessory
organ, and genitourinary studies including equipment, protocol, dose,
administration technique, administration-to-acquisition times, acquisition
parameters, standard positioning, special imaging adaptations, data
processing and potential pitfalls. (III- VII, XXIII-XXX) |
|
9.
|
Recognize the normal distribution, normal variants and
various artifacts seen on selected endocrine/exocrine,
gastrointestinal/accessory organ, and genitourinary systems and printed
images. (III-VII, XXIII-XXX) |
|
10.
|
Describe possible sources of error in selected
endocrine/exocrine, gastrointestinal/accessory organ and genitourinary
studies. (III, XXV, XXVI, XXVII, XXVIII) |
|
11.
|
Discuss the diagnostic and prognostic value of selected endocrine/exocrine,
gastrointestinal/accessory organ, and genitourinary studies. (III-VII,
XXIII-XXX) |
|
12.
|
Discuss common causes of false-negative and false-positive
thyroid uptake results. (III-VII, XXIII-XXX) |
|
13.
|
Describe the interventional procedures that may be used
for selected endocrine/exocrine, gastrointestinal/accessory organ, and
genitourinary studies. (X, XI, XVI, XVIII) |
|
14.
|
Describe the appearance of various pathologies seen on
selected endocrine/exocrine, gastrointestinal/accessory organ, and
genitourinary studies and printed images. (X-XX, XXV-XXIX) |
|
15.
|
Describe special radiation safety precautions considered
when performing selected endocrine/exocrine, gastrointestinal/accessory
organ, and genitourinary studies. (XI, XII, XIII) |
|
16.
|
Calculate esophageal transit and emptying times and
percent esophageal reflux and emptying. (XI) |
|
17.
|
Identify structures on hemangioma
detection single photon emission computed tomography (SPECT) slices. (XV) |
|
18.
|
Calculate gall bladder ejection fraction. (XVI) |
|
19.
|
Describe standard preparation and method for tagging and
denaturing red blood cells for selective spleen imaging. (XXIX) |
|
20.
|
Describe the procedures related to ablation for
hyperthyroidism. (XXI) |
|
21.
|
Describe the procedures related to thyroid carcinoma
ablation. (XXII) |
|
22.
|
Discuss the relationship between renal activity and aldosterone, renin-angiotensin
and ADH. (XXIII) |
|
23.
|
Describe the effects of diuretics on renal function.
(XXIII) |
|
24.
|
Discuss factors that contribute to success or failure of
transplanted kidneys. (XXIII) |
|
25.
|
Describe the interventional procedures that may be used
for performing renograms. (XXIV) |
Go to Description Go to top of
Competencies
|
MCCCD
Official Course Outline: |
||
|
|
||
|
DMI271 2006
Summer I – 2009 Summer II |
Nuclear Medicine Imaging II |
|
|
||
|
I. Review of
Endocrine/Exocrine Anatomy and Physiology A. Gross structure and
function of glands B. Cellular anatomy and
function II. Review of
Endocrine/Exocrine Pathology A. Thyroid B. Parathyroid C. Adrenal D. Lacrimal
duct obstruction III. Thyroid Uptake Study A. Indications B. Radiopharmaceuticals 1. Tracers 2. Dose range and route of administratioin 3. Diorouting
4. Dosimetry
C. Contraindications and
adverse reactions D. Equipment E. Basic procedures and
processing F. Interpretation of data G. Normal range H. Normal variants I. Abnormal J. Sources of error K. Diagnostic/Prognostic
Value of the Study IV. Thyroid Scan A. Indications B. Radiopharmaceuticals 1. Tracers 2. Dose range and route of administratioin 3. Biorouting
4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparations E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Image formatting 6. Pitfalls G. Interpretation of images
1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis V. Parathyoid
Imaging A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m sestamibi b. Tc-99m sestamibi/I-123 sodium iodide c. Tc099m sestamibi/Tl-201 thallous
chloride d. Tc099m pertechnetate/Tl-201 thallous
chloride 2. Dose range and route of administratioin 3. Biorouting
4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Image formatting 6. Pitfalls G. Interpretation of images
1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis VI. Adrenal Imaging A. Indications B. Radiopharmaceuticals 1. Tracers a. I-123 MIBG (metaiodobenzylguanidine) b. I-131 MIBG c. I-131 norcholestrol 2. Dose range and route of administratioin 3. Biorouting
4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Image formatting 6. Pitfalls G. Interpretation of images
1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis VII. Lacrimal
Duct Imaging (Dacryoscintigraphy) A. Indications B. Radiopharmaceuticals 1. Tracer: Tc-99m pertechnetate 2. Physical and chemical
characteristics 3. Radiopharmaceutical
preparation 4. Dose range and route of
administration 5. Biorouting
6. Dosimetry
C. Contraindications and
adverse reactions 1. Physical conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Image formatting 6. Pitfalls G. Interpretation of images
1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis VIII.
Gastrointestinal/Accessory Organ Review of Anatomy and Physiology A. Gross anatomy and
physiology B. Cellular anatomy and
function C. Blood flow D. Bile production IX. Review of
Gastrointestinal/Accessory Organ Pathology A. Primary and metastatic neoplasms B. Salivary gland disorders
1. Sjogren's
disease 2. Warthin's
tumor 3. Obstruction 4. Space occupying C. Disorders of the
esophagus 1. Gastroesophageal
reflux disease 2. esophagitis
3. achalasia
4. scleroderma 5. Barrett's esophagus D. Gastric disorders 1. delayed emptying 2. "dumping"
syndrome 3. peptic ulcer E. Liver and gallbladder 1. infections 2. circulatory disorders 3. cirrhosis 4. cholecystitis
5. cholelithiasis
6. congenital abnormalities
7. tumors a. primary b. metastatic c. hemangioma
8. Budd-Chiari
syndrome F. Splenic
disease 1. splenomegaly
2. space occupying lesions 3. asplenia
4. accessory spleen G. Gastrointestinal (GI)
Hemorrhage H. Meckel's
diverticulum X. Salivary Gland Imaging A. Indications B. Radiopharmaceuticals 1. Tracers a. I-123 MIBG (metaiodobenzylguanidine) b. I-131 MIBG c. I-131 norcholestrol 2. Dose range and route of administratioin 3. Biorouting
4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Image formatting 6. Pitfalls G. Interpretation of images
1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XI. Esophageal
Motility/Transit and Reflux A. Indications B. Radiopharmaceuticals 1. Tracer: Tc-99m sulfur
colloid (SC) 2. Dose range and route of administratioin 3. Biorouting
a. distribution b. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical and pathologic
conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Special radiation safety
considerations E. Patient preparation F. Equipment 1. camera 2. collimators 3. computer G. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations a. motility and transit b. reflux c. pumonary
5. Data processing 6. Image formatting 7. Pitfalls H. Interventions and
procedures I. Interpretation of images
and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XII. Gastric Emptying A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m sulfur colloid
(solid) b. In-111DTPA (liquid) 2. Dose range and route of administratioin 3. Biorouting
a. distribution b. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical and pathologic
conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Special radiation safety
considerations E. Patient preparation F. Equipment 1. camera 2. collimators 3. computer G. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Data processing 6. Image formatting 7. Pitfalls H. Interpretation of images
and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic risk factors
based on diagnosis a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XIII. Helicobacter Pylori
Detection A. Indications B. Radiopharmaceutical 1. Carbon-14 labeled area 2. Dose range and route of administratioin 3. Biorouting
a. distribution b. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical and pathologic
conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Special radiation safety
considerations E. Patient preparation F. Equipment 1. camera 2. collimators 3. computer G. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Data processing 6. Image formatting 7. Pitfalls H. Interpretation of images
and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic risk factors
based on diagnosis a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XIV. Liver/Spleen A. Indications B. Radiopharmaceutical 1. Tc-99 sulfur colloid 2. Dose range and route of administratioin 3. Biorouting
a. distribution b. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical and pathologic
conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. collimators 2. computer F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters G. Interpretation of images
and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic risk factors
based on diagnosis a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XV. Hemangioma
Detection A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m labeled red blood
cells b. Tc-99m sulfur colloid 2. Dose range and route of administratioin 3. Biorouting
a. uptake b. distribution c. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical and pathologic
conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Data processing 6. Image formatting 7. Pitfalls G. Interpretation of images
and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic risk factors
based on diagnosis a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XVI. Hepatobiliary
Imaging A. Indications B. Radiopharmaceuticals 1. Tc-99m IDA (iminodiacetic acid) derivatives (ex.Tc-99m disofenin) 2. Dose range and route of administratioin 3. Biorouting
a. uptake b. distribution c. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical and pathologic
conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Data processing 6. Image formatting 7. Pitfalls G. Intervention and
procedures 1. morphine enhanced 2. cholecystokinin
intervention 3. quantitation
(gallbladder ejection fraction) H. Interpretation of images
and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic risk factors
based on diagnosis a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XVII. Gastrointestinal (GI)
Hemorrhage A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m sulfur colloid b. Tc-99m labeled red blood
cells 2. Dose range and route of administratioin 3. Biorouting
a. uptake b. distribution c. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical and pathologic
conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Data processing 6. Image formatting 7. Pitfalls G. Interpretation of images
and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic risk factors
based on diagnosis a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XVIII. Meckel's
diverticulum A. Indications B. Radiopharmaceuticals 1. Tc-99m pertechnetate 2. Radiopharmaceutical
preparation 3. Dose range and route of
administration 4. Biorouting
a. uptake b. distribution c. excretion 5. Dosimetry
C. Contraindications and
adverse reactions 1. Physical and pathologic
conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Data processing 6. Image formatting 7. Pitfalls G. Interventions and
procedures 1. glucagon 2. cimetidine
3. pentagastrin
H. Interpretation of images
and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic risk factors
based on diagnosis a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XIX. LeVeen
Shunt A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m MAA b. Tc-99m sulfur colloid 2. Dose range and route of
administration 3. Biorouting
a. uptake b. distribution c. excretion 4. Dosimtery
C. Contraindications and
adverse reactions 1. Physical and pathologic
conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Special radiation safety
considerations E. Patient preparation F. Equipment 1. camera 2. collimators 3. computer G. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Data processing 6. Image formatting 7. Pitfalls H. Interpretation of images
and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic risk factors
based on diagnosis a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XX. Intahepatic
pump study A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m Macroaggregated albumin (MAA) b. Tc-99m sulfur colloid 2. Dose range and route of
administration 3. Biorouting
a. uptake b. distribution c. excretion 4. Dosimtery
C. Contraindications and
adverse reactions 1. Interfering studies 2. Precautions 3. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Image formatting 6. Pitfalls G. Interpretation of images
and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic risk factors
based on diagnosis a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XXI. Ablation for
Hyperthyroidism A. Indications B. Radiopharmaceuticals 1. Iodine-131 (I-131)
sodium iodide 2. Physical and chemical
characteristics 3. Radionuclide
preparations 4. Dose range and route of
administration 5. Biorouting
a. uptake b. distribution c. excretion 6. Dosimetry
C. Contraindications and
adverse reactions 1. Physical and pathologic
conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse Reactions D. Special radiation safety
considerations and regulations E. Patient preparation
(including consent) F. Basic procedure 1. Protocols 2. Dose range and
administration technique 3. Pitfalls G. Prognostic Value 1. outcomes 2. treatment decisions 3. prognostic risk factors
based on diagnosis XXII. Thyroid Carcinoma
Ablation A. Indications B. Radiopharmaceuticals 1. Iodine-131 sodium iodide
2. Physical and chemical
characteristics 3. Radionuclide preparation
4. Dose range and route of
administration 5. Biorouting
a. uptake b. distribution c. excretion 6. Dosimetry
C. Contraindications and
adverse reactions 1. Physical and pathologic
conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse Reactions D. Special radiation safety
considerations and regulations E. Patient preparation
(including consent) F. Basic procedure 1. Protocols 2. treatment decisions 3. prognostic risk factors
based on diagnosis G. Prognostic Value 1. outcomes 2. treatment decisions 3. prognostic risk factors
based on diagnosis XXIII. Genitourinary System
A. Review of Anatomy and
Physiology of the Genitourinary System 1. Gross structure and
function 2. Cellular structure and
function 3. Blood flow XXIV. Genitourinary System
Pathology A. Acute inflammatory
disease B. Chronic inflammatory
disease C. Acute tubular necrosis D. Congenital abnormalities
E. Space occupying lesions F. Renal cancers G. Renovascular
disease H. Obstructive uropathies I. Renal transplant and
rejection J. Vesicourethral
reflux K. Testicular torsion L. Inflammatory diseases of
the testes XXV. Renal Perfusion Study A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m sodium pertechnetate b. Tc-99m Diethylenetriaminepentaacetate (DTPA) c. Tc-99m gluceptate (GH) d. Tc-99m MAG3 (mercaptoacetylglycylglycylglycine) e. Tc-99m succimer (DMSA) 2. Physical and chemical
characteristics 3. Dose range and route of
administration 4. Biorouting
a. uptake b. distribution c. excretion 5. Dosimetry
C. Contraindications and
adverse reactions 1. Physical conditions 2. Interfering studies 3. Precautions 4. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. protocols 2. dose and administration
technique 3. acquisition parameters 4. positioning and views,
including adaptations 5. data processing 6. image formatting 7. pitfalls G. Interpretation of images
and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
value of study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XXVI. Renogram
A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m DTPA b. Tc-99m gluceptate (GH) c. Tc-99m MAG3 (mercaptoacetylglycylglycylglycine) 2. Physical and chemical
characteristics 3. Dose range and route of
administration 4. Biorouting
a. uptake b. distribution c. excretion 5. Dosimetry
C. Contraindications and
adverse reactions 1. Physical conditions 2. Interfering studies 3. Precautions 4. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. protocols 2. dose and administration
technique 3. acquisition parameters 4. positioning and views,
including adaptations 5. data processing 6. image formatting 7. pitfalls G. Interventions and
procedures 1. captopril
2. enalapril
3. furosemide
H. Interpretation of images
and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
value of study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XXVII. Glomerular
Filtration Rate (GFR) and Effective Renal Plasma Flow (ERPF) A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m DTPA b. Tc-99m MAG3 (mercaptoacetylglycylglycylglycine) 2. Physical and chemical
characteristics 3. Kit and
radiopharmaceutical preparation 4. Dose range and route of
administration 5. Biorouting
a. uptake b. distribution c. excretion 6. Dosimetry
C. Contraindications and
adverse reactions 1. Physical conditions 2. Interfering studies 3. Precautions 4. Adverse reactions D. Patient preparation E. Equipment 1. imaging equipment 2. laboratory equipment F. Basic procedure and
processing 1. protocols 2. dose and administration
technique 3. acquisition parameters 4. positioning and views,
including adaptations 5. data processing 6. pitfalls G. Interventions and
procedures 1. captopril
2. enalapril
3. furosemide
H. Interpretation of images
and data 1. Normal 2. Normal variants 3. Abnormal 4. Sources of error 5. Diagnostic/Prognostic
value of study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XXVIII. Renal Scan for
Morphology A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m DMSA b. Tc-99m gluceptate (GH) 2. Physical and chemical
characteristics 3. Dose range and route of
administration 4. Biorouting
a. uptake b. distribution c. excretion 5. Dosimetry
C. Contraindications and
adverse reactions 1. Physical conditions 2. Interfering studies 3. Precautions 4. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. protocols 2. dose and administration
technique 3. acquisition parameters 4. positioning and views,
including adaptations 5. data processing 6. image formatting 7. pitfalls G. Interpretation of images
and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
value of study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XXIX. Voiding Cystogram A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m DTPA b. Tc-99m sodium pertechnetate 2. Physical and chemical
characteristics 3. Kit and
radiopharmaceutical preparation 4. Dose range and route of
administration 5. Biorouting
a. uptake b. distribution c. excretion 6. Dosimetry
C. Contraindications and
adverse reactions 1. Physical conditions 2. Interfering studies 3. Precautions 4. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer 4. lab equipment F. Basic procedure and
processing 1. protocols a. direct b. indirect 2. dose and administration
technique 3. acquisition parameters 4. positioning and views,
including adaptations 5. data processing 6. image formatting 7. pitfalls G. Interpretation of images
and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
value of study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XXX. Testicular Imaging A. Indications B. Radiopharmaceuticals 1. Tc-99m sodium pertechnetate 2. Physical and chemical
characteristics 3. Radiopharmaceutical
preparation 4. Dose range and route of
administration 5. Biorouting
a. uptake b. distribution c. excretion 6. Dosimetry
C. Contraindications and
adverse reactions 1. Interfering studie 2. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. protocols 2. dose and administration
technique 3. acquisition parameters 4. positioning and views,
including adaptations 5. image formatting 6. pitfalls G. Interpretation of images
and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
value of study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis |
|
|